Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma

Inclusion Criteria: * The patient has the willingness to communicate with the investigator, can understand and follow the trial requirements, is willing to participate in the trial, understands and signs a written Informed Consent Form（ICF）, and is willing and able to comply with the visit schedule, administration plan, laboratory examination, and other clinical trial procedures. * Gender: Male or female. * Age 18-70 years old. * Expected survival ≥ 12 weeks. * Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Patients with advanced solid tumors or NHL by histopathological diagnosis do not have acceptable standard treatment currently. * Adequate organ function per protocol-defined criteria. Exclusion Criteria: * Use of protocol-defined prior/concomitant therapy. * Currently receiving or has received an investigational treatment as part of a study within 4 weeks before the first dosing. * History of severe hypersensitivity reaction to study treatments or their excipients. * Known active central nervous system metastases. * History of any active autoimmune disease history, or disease or syndrome requiring treatment with systemic steroids or immunosuppressive medications. * Presence of active infection. * Known additional malignancy that has not been cured in the last 5 years. * Any uncontrolled intercurrent illness or condition that in the judgment of the Investigator may endanger the patient.